NasdaqGM:SMMTBiotechs
Summit Therapeutics (SMMT) Updates Ivonescimab Progress, Is The 52% Undervalued View Convincing?
Summit Therapeutics (SMMT) has drawn fresh attention after updated Phase III HARMONi overall survival data for ivonescimab, a set PDUFA date, and a new collaboration with Arcus Biosciences in metastatic kidney cancer.
See our latest analysis for Summit Therapeutics.
Despite the recent clinical and regulatory updates, Summit Therapeutics' 1-day share price return declined 8.81% to close at US$13.66, and its 90-day share price return is down 35.75%. However, the 3-year total shareholder return...